The standardized name of the nine-valent vaccine is Nine-valent Cervical Cancer Vaccine (NVCCV), and its third dose is given four months apart from the second dose.
Nine types of cervical cancer vaccine, including cervical cancer subtypes 6, 11, 16, 18, 31, 33, 45, 52 and 58, is the most comprehensive cervical cancer vaccine available, and is effective in the prevention of cervical cancer and condyloma acuminatum.
The vaccine is suitable for women aged 16-26 years and is generally recommended to be administered at 0, 2 and 6 months of age. 0 is the initial injection, 2 months after the first injection, the second injection, 6 months after the first injection, and the third injection at 6 months after the first injection (and the third injection at 4 months after the second injection), and women can complete all three injections within six months if they strictly follow this cycle.
If vaccination is needed, it is recommended to follow this cycle strictly under the supervision of a doctor to minimize the risk of exposure to infection.